Cereno Scientific expands patent protection for PAH drug candidate CS1:s second and third patent family
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for rare and common cardiovascular disease, today announced two new granted patents; a patent in CS1:s second patent family has been issued in New Zealand and a second patent in CS1:s third patent family has been issued in the US.“I am delighted to announce two new patents for our leading drug candidate, CS1, in Phase II development for the rare disease Pulmonary Arterial Hypertension (PAH). Our continuous work in securing a strong IPR portfolio has resulted in yet another expansion of CS1’